Adial Pharmaceuticals Files 8-K with Agreement Changes
Ticker: ADIL · Form: 8-K · Filed: Dec 18, 2024 · CIK: 1513525
| Field | Detail |
|---|---|
| Company | Adial Pharmaceuticals, Inc. (ADIL) |
| Form Type | 8-K |
| Filed Date | Dec 18, 2024 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $5,000,000, $10,000,000, $0.001, $500,000, $1,250,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
Adial Pharma 8-K: Signed new deal, ditched old one, sold some stock. Details TBD.
AI Summary
On December 13, 2024, Adial Pharmaceuticals, Inc. entered into a Material Definitive Agreement and also terminated a Material Definitive Agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. Specific details regarding the nature of these agreements and sales were not provided in this filing summary.
Why It Matters
This filing indicates significant changes in Adial Pharmaceuticals' contractual relationships and potential equity transactions, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing mentions both the entry into and termination of material definitive agreements, alongside unregistered sales of equity, suggesting potential shifts in business strategy or financial arrangements that warrant closer examination.
Key Players & Entities
- Adial Pharmaceuticals, Inc. (company) — Registrant
- December 13, 2024 (date) — Earliest event reported
FAQ
What was the nature of the Material Definitive Agreement entered into by Adial Pharmaceuticals on December 13, 2024?
The filing states that Adial Pharmaceuticals, Inc. entered into a Material Definitive Agreement on December 13, 2024, but the specific terms and nature of this agreement are not detailed in the provided summary.
What were the reasons for the termination of a Material Definitive Agreement by Adial Pharmaceuticals?
The filing indicates the termination of a Material Definitive Agreement by Adial Pharmaceuticals on December 13, 2024, but the reasons for this termination are not specified in the provided summary.
What type of equity securities were sold by Adial Pharmaceuticals, and under what terms?
The filing reports unregistered sales of equity securities by Adial Pharmaceuticals, Inc., but the specific details regarding the type of securities and the terms of the sale are not disclosed in the provided summary.
Are the financial statements and exhibits filed with this 8-K report expected to show significant changes?
The filing indicates that financial statements and exhibits were filed as part of this 8-K report, but the content or expected impact of these filings is not detailed in the provided summary.
Does the 8-K filing provide any information about the company's financial performance or outlook?
While the filing mentions the submission of financial statements and exhibits, the provided summary does not contain specific details about Adial Pharmaceuticals' financial performance or outlook.
Filing Stats: 2,077 words · 8 min read · ~7 pages · Grade level 14.6 · Accepted 2024-12-18 17:00:09
Key Financial Figures
- $5,000,000 — Alumni Capital up to the lesser of (i) $5,000,000 of newly issued shares, subject to incr
- $10,000,000 — y issued shares, subject to increase to $10,000,000 at the option of the Company (the "Inve
- $0.001 — f the Company's common stock, par value $0.001 per share (the "Common Stock"), and (ii
- $500,000 — hase will not exceed the greater of (i) $500,000 and (ii) 150% of the average daily trad
- $1,250,000 — e fixed purchase will in no case exceed $1,250,000 or, with mutual agreement of Alumni Cap
- $2,500,000 — ith mutual agreement of Alumni Capital, $2,500,000. The purchase price per Share that ma
- $0.55 — no time can the purchase price be below $0.55 per share (subject to adjustment as pro
- $1.09 — or exceeds the Minimum Price, which is $1.09. If stockholders approval to exceed the
Filing Documents
- ea0225021-8k_adialpharm.htm (8-K) — 53KB
- ea022502101ex10-1_adialpharm.htm (EX-10.1) — 143KB
- ea022502101ex10-2_adialpharm.htm (EX-10.2) — 9KB
- 0001213900-24-110191.txt ( ) — 417KB
- adil-20241213.xsd (EX-101.SCH) — 3KB
- adil-20241213_lab.xml (EX-101.LAB) — 33KB
- adil-20241213_pre.xml (EX-101.PRE) — 22KB
- ea0225021-8k_adialpharm_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 18, 2024 ADIAL PHARMACEUTICALS, INC. By: /s/ Cary J. Claiborne Name: Cary J. Claiborne Title: President and Chief Executive Officer 4